Tumor-Elicited Inflammation and Colorectal Cancer.

[1]  M. Karin,et al.  Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. , 2014, Immunity.

[2]  R. Nurieva,et al.  Interleukin (IL)-21 promotes intestinal IgA response to microbiota , 2014, Mucosal Immunology.

[3]  Qingsheng Li,et al.  Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. , 2014, Cancer research.

[4]  K. Rajewsky,et al.  STAT3 Activation in Th17 and Th22 Cells Controls IL-22–Mediated Epithelial Host Defense during Infectious Colitis , 2014, The Journal of Immunology.

[5]  R. Savan,et al.  The role of the IL-22/IL-22R1 axis in cancer. , 2014, Cytokine & growth factor reviews.

[6]  Q. Zhang,et al.  Interleukin‐17 promotes development of castration‐resistant prostate cancer potentially through creating an immunotolerant and pro‐angiogenic tumor microenvironment , 2014, The Prostate.

[7]  A. Maitra,et al.  Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.

[8]  Y. Dou,et al.  IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. , 2014, Immunity.

[9]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[10]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[11]  W. Ouyang,et al.  Therapeutic opportunities of the IL-22–IL-22R1 system , 2013, Nature Reviews Drug Discovery.

[12]  J. Gilbert,et al.  Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. , 2013, Cancer research.

[13]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[14]  S. Grivennikov.  IL-11: a prominent pro-tumorigenic member of the IL-6 family. , 2013, Cancer cell.

[15]  C. Harrison.  Cancer: IL-22: linking inflammation and cancer , 2013, Nature Reviews Drug Discovery.

[16]  W. Ouyang,et al.  IL-22–producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis , 2013, Proceedings of the National Academy of Sciences.

[17]  Lian Yu,et al.  Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. , 2013, World journal of gastroenterology.

[18]  F. Powrie,et al.  Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model , 2013, The Journal of experimental medicine.

[19]  Yongzhong Liu,et al.  Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. , 2013, Clinical immunology.

[20]  Tao Ren,et al.  IL-17 promoted metastasis of non-small-cell lung cancer cells. , 2012, Immunology letters.

[21]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[22]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[23]  J. Kolls,et al.  Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.

[24]  K. Mills,et al.  IL‐17‐producing γδ T cells and innate lymphoid cells , 2012, European journal of immunology.

[25]  Francis J. Huber,et al.  IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine , 2012, Nature.

[26]  D. Littman,et al.  Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications , 2012, European journal of immunology.

[27]  V. Kuchroo,et al.  IL-12 family cytokines: immunological playmakers , 2012, Nature Immunology.

[28]  Xuexian O Yang,et al.  A Protective Role by Interleukin-17F in Colon Tumorigenesis , 2012, PloS one.

[29]  C. Elmets,et al.  IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin , 2012, PloS one.

[30]  A. Rizzo,et al.  Involvement of interleukin-21 in the regulation of colitis-associated colon cancer , 2011, The Journal of experimental medicine.

[31]  A. Bothwell,et al.  IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice. , 2011, Biochemical and biophysical research communications.

[32]  K. Mills,et al.  Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. , 2011, Cytokine.

[33]  G. Schiechl,et al.  Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice , 2011, Gut.

[34]  D. Han,et al.  Role of IL-17A in the development of colitis-associated cancer. , 2011, Carcinogenesis.

[35]  Dan R. Littman,et al.  Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity , 2011, Nature.

[36]  Dušica Vidović,et al.  Suppression of TH17 Differentiation and Autoimmunity by a Synthetic ROR Ligand , 2011, Nature.

[37]  Yoichiro Iwakura,et al.  Review Functional Specialization of Interleukin-17 Family Members , 2022 .

[38]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[39]  Hua Yu,et al.  IL-17 enhances tumor development in carcinogen-induced skin cancer. , 2010, Cancer research.

[40]  C. Dong,et al.  IL-17 family member cytokines: regulation and function in innate immunity. , 2010, Cytokine & growth factor reviews.

[41]  M. Cottone,et al.  Investigational agents for Crohn's disease , 2010, Expert opinion on investigational drugs.

[42]  F. Marincola,et al.  MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18 , 2010, The Journal of experimental medicine.

[43]  C. Tato,et al.  Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.

[44]  T. Kishimoto.  IL-6: from its discovery to clinical applications. , 2010, International immunology.

[45]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[46]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[47]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[48]  D. Zelterman,et al.  Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[49]  A. Schetter,et al.  Association of Inflammation-Related and microRNA Gene Expression with Cancer-Specific Mortality of Colon Adenocarcinoma , 2009, Clinical Cancer Research.

[50]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[51]  T. Strom,et al.  T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. , 2009, Cancer research.

[52]  A. Tenesa,et al.  New insights into the aetiology of colorectal cancer from genome-wide association studies , 2009, Nature Reviews Genetics.

[53]  S. Spechler,et al.  Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer , 2009, Nature Reviews Gastroenterology &Hepatology.

[54]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[55]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[56]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[57]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[58]  Charles Giardina,et al.  Mouse models for the study of colon carcinogenesis. , 2008, Carcinogenesis.

[59]  B. Czerniecki,et al.  Differential Production of IL-23 and IL-12 by Myeloid-Derived Dendritic Cells in Response to TLR Agonists1 , 2008, The Journal of Immunology.

[60]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[61]  P. Lakatos,et al.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. , 2008, World journal of gastroenterology.

[62]  R. Broaddus,et al.  Regulation of inflammatory responses by IL-17F , 2008, The Journal of experimental medicine.

[63]  J. Davis,et al.  Interleukin-6 and cachexia in ApcMin/+ mice. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[64]  N. Mukaida,et al.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. , 2008, The Journal of clinical investigation.

[65]  A. Rustgi,et al.  The genetics of hereditary colon cancer. , 2007, Genes & development.

[66]  Kathleen R. Cho,et al.  Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. , 2007, Cancer research.

[67]  Terry B. Strom,et al.  IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells , 2007, Nature.

[68]  A. D. Panopoulos,et al.  Essential autocrine regulation by IL-21 in the generation of inflammatory T cells , 2007, Nature.

[69]  R. Medzhitov,et al.  Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88 , 2007, Science.

[70]  R. Carmody,et al.  Essential Roles of c-Rel in TLR-Induced IL-23 p19 Gene Expression in Dendritic Cells1 , 2007, The Journal of Immunology.

[71]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[72]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[73]  T. Wynn,et al.  The IL-21 receptor augments Th2 effector function and alternative macrophage activation. , 2006, The Journal of clinical investigation.

[74]  J. Meijerink,et al.  Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. , 2006, Gastroenterology.

[75]  M. Vander Vliet,et al.  A phase 1/2A Trial of STA 5326, an oral interleukin‐12/23 inhibitor, in patients with active moderate to severe Crohn's disease , 2006, Inflammatory bowel diseases.

[76]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[77]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[78]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[79]  Jane J. Sohn,et al.  CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. , 2005, Cancer research.

[80]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[81]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[82]  P. Lipsky,et al.  Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-61 , 2004, The Journal of Immunology.

[83]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[84]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[85]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[86]  F. Balkwill,et al.  Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development , 2004, Oncogene.

[87]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[88]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[89]  Takuji Tanaka,et al.  A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate , 2003, Cancer science.

[90]  G. Trinchieri,et al.  The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. , 2003, Immunity.

[91]  J. Fox,et al.  CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. , 2003, Cancer research.

[92]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[93]  Lyle L. Moldawer,et al.  Anti-TNF-α therapies: the next generation , 2003, Nature Reviews Drug Discovery.

[94]  C. Hong,et al.  Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX‐2 inhibitor , 2003, Cancer science.

[95]  J. Fox,et al.  CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. , 2003, The American journal of pathology.

[96]  A. Sher,et al.  A Critical Role for IL-21 in Regulating Immunoglobulin Production , 2002, Science.

[97]  M. Mai,et al.  Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. , 2002, Cancer research.

[98]  S. Arico,et al.  Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line* , 2002, The Journal of Biological Chemistry.

[99]  T. Mcclanahan,et al.  A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.

[100]  Jeffrey L. Wrana,et al.  Signal Transduction by the TGF-β Superfamily , 2002, Science.

[101]  Kan Yang,et al.  Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2 , 2002, Science.

[102]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[103]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[104]  D. Lejeune,et al.  Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22 , 2001, The Journal of Immunology.

[105]  C. Davis,et al.  Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. , 2001, Critical reviews in oncology/hematology.

[106]  S. Pestka,et al.  Identification of the Functional Interleukin-22 (IL-22) Receptor Complex , 2001, The Journal of Biological Chemistry.

[107]  N. Fausto,et al.  Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.

[108]  Scott R. Presnell,et al.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function , 2000, Nature.

[109]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[110]  W. Leonard,et al.  Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Zemin Zhang,et al.  Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2–4 and IL-22R* , 2000, The Journal of Biological Chemistry.

[112]  J. Massagué,et al.  Controlling TGF-β signaling , 2000, Genes & Development.

[113]  M. Washington,et al.  Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. , 2000, Gastroenterology.

[114]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[115]  A. Roberts,et al.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β , 1999, The EMBO journal.

[116]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[117]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[118]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[119]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[120]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[121]  M. Leach,et al.  T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice , 1996, The Journal of experimental medicine.

[122]  Anita B. Roberts,et al.  Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .

[123]  J. Eshleman,et al.  Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. , 1995, Cancer research.

[124]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[125]  C. Begley,et al.  Cloning of a murine IL‐11 receptor alpha‐chain; requirement for gp130 for high affinity binding and signal transduction. , 1994, The EMBO journal.

[126]  J. Massagué,et al.  The TGF-β family and its composite receptors , 1994 .

[127]  M. Lindstrom,et al.  ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[128]  M. Tsang,et al.  Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. , 1993, Journal of immunology.

[129]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[130]  T. Mosmann,et al.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.

[131]  Harold L. Moses,et al.  TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights , 1990, Cell.

[132]  M. Kirschner,et al.  Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early xenopus embryo , 1987, Cell.

[133]  L. Old,et al.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[134]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[135]  G. H. Algire,et al.  Vascular reactions of normal and malignant tissues in vivo. V. The rôle of hypotension in the action of a bacterial polysaccharide on tumors. , 1952, Journal of the National Cancer Institute.

[136]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[137]  Oliver Sartor,et al.  Molecular and Cellular Pathobiology Interleukin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models , 2012 .

[138]  H. Lodish.  Molecular Cell Biology , 1986 .